Safety of an oral chondroprotective agent in horses.
Six healthy, adult female horses were administered five times the minimum maintenance dose of an oral low-molecular-weight chondroitin sulfate, glucosamine HCl, and manganese ascorbate chondroprotective agent (Cosequin; Nutramax Laboratories, Inc., Edgewood, MD) daily for 35 days. Hematology, serum biochemistry, and synovial fluid parameters were assessed twice prior to administering the product and again at the end of the treatment period. Physical examinations performed daily throughout the study showed no abnormal clinical changes attributable to the product. All hematologic parameters measured were within normal reference ranges; however, hematocrit, hemoglobin, and white blood cell counts were significantly (P < .05) increased after treatment, as compared with values on Day 0. Mean serum urea nitrogen was mildly elevated above the reference range before and after treatments, and mean serum creatinine was significantly (P < .05) decreased after treatment. Several other biochemical parameters (calcium, phosphorus, potassium, total and indirect bilirubin, alkaline phosphatase, gamma-glutamyltransferase, lactic dehydrogenase, and sodium:potassium ratio) were significantly (P < .05) altered following administration of the chondroprotectant, but all remained within normal reference ranges. Mean creatine kinase levels were significantly higher after treatment than on Day 0 (429 U/L versus 310 U/L), but this represented only a mild elevation relative to the reference range (10 to 350 U/L). Synovial fluid total protein and specific gravity were unaffected. The minor shifts encountered in hematology and serum biochemistry parameters are not considered to have clinical significance. The results of this study suggest that the oral chondroprotective agent tested is safe for administration to horses at recommended dose rates.
Kirker-Head
C A
CA
Tufts University, School of Veterinary Medicine, Department of Clinical Sciences, 200 Westborough Road, North Grafton, MA 01536, USA.
Kirker-Head
R P
RP
D000284:Administration, Oral; D000818:Animals; D002809:Chondroitin Sulfates / Q000008:administration & dosage / Q000009:adverse effects* / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D005260:Female; D005944:Glucosamine / Q000008:administration & dosage / Q000009:adverse effects* / Q000494:pharmacology*; D006736:Horses; D008345:Manganese / Q000008:administration & dosage / Q000009:adverse effects* / Q000494:pharmacology*
D004338:Drug Combinations; D008345:Manganese; D002809:Chondroitin Sulfates; D005944:Glucosamine